<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36555655</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>24</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>16</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Anti-SOD1 Nanobodies That Stabilize Misfolded SOD1 Proteins Also Promote Neurite Outgrowth in Mutant SOD1 Human Neurons.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">16013</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms232416013</ELocationID><Abstract><AbstractText>ALS-linked mutations induce aberrant conformations within the SOD1 protein that are thought to underlie the pathogenic mechanism of SOD1-mediated ALS. Although clinical trials are underway for gene silencing of <i>SOD1</i>, these approaches reduce both wild-type and mutated forms of SOD1. Here, we sought to develop anti-SOD1 nanobodies with selectivity for mutant and misfolded forms of human SOD1 over wild-type SOD1. Characterization of two anti-SOD1 nanobodies revealed that these biologics stabilize mutant SOD1 in vitro. Further, SOD1 expression levels were enhanced and the physiological subcellular localization of mutant SOD1 was restored upon co-expression of anti-SOD1 nanobodies in immortalized cells. In human motor neurons harboring the <i>SOD1 A4V</i> mutation, anti-SOD1 nanobody expression promoted neurite outgrowth, demonstrating a protective effect of anti-SOD1 nanobodies in otherwise unhealthy cells. In vitro assays revealed that an anti-SOD1 nanobody exhibited selectivity for human mutant SOD1 over endogenous murine SOD1, thus supporting the preclinical utility of anti-SOD1 nanobodies for testing in animal models of ALS. In sum, the anti-SOD1 nanobodies developed and presented herein represent viable biologics for further preclinical testing in human and mouse models of ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Meenakshi Sundaram</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biochemistry and Molecular Biotechnology Program, Morningside Graduate School of Biomedical Sciences, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fowler-Magaw</LastName><ForeName>Megan E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0002-3774-3137</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Program, Morningside Graduate School of Biomedical Sciences, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kulick</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biology, Neuroscience and Behavior Program, Wesleyan University, Middletown, CT 06459, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boopathy</LastName><ForeName>Sivakumar</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0524-3338</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biochemistry and Molecular Biotechnology Program, Morningside Graduate School of Biomedical Sciences, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gadd</LastName><ForeName>Del Hayden</ForeName><Initials>DH</Initials><Identifier Source="ORCID">0000-0001-8279-7065</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rotunno</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biochemistry and Molecular Biotechnology Program, Morningside Graduate School of Biomedical Sciences, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Douthwright</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biochemistry and Molecular Biotechnology Program, Morningside Graduate School of Biomedical Sciences, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golebiowski</LastName><ForeName>Diane</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-5550-7883</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yusuf</LastName><ForeName>Issa</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Zuoshang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sena-Esteves</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Neil</LastName><ForeName>Alison L</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0002-0759-4740</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Neuroscience and Behavior Program, Wesleyan University, Middletown, CT 06459, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosco</LastName><ForeName>Daryl A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM137529</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS120126</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001453</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM147677</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS108769</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS101895</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS067206</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS118145</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061905">Single-Domain Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061905" MajorTopicYN="Y">Single-Domain Antibodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071446" MajorTopicYN="N">Neuronal Outgrowth</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS) (Lou Gehrig disease)</Keyword><Keyword MajorTopicYN="N">antibody engineering</Keyword><Keyword MajorTopicYN="N">neurite outgrowth</Keyword><Keyword MajorTopicYN="N">protein misfolding</Keyword><Keyword MajorTopicYN="N">superoxide dismutase (SOD)</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>23</Day><Hour>1</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36555655</ArticleId><ArticleId IdType="pmc">PMC9784173</ArticleId><ArticleId IdType="doi">10.3390/ijms232416013</ArticleId><ArticleId IdType="pii">ijms232416013</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown R.H., Al-Chalabi A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardo C.A., Xu Z., Borchelt D.R., Price D.L., Sisodia S.S., Cleveland D.W., Brown R., Price D., Sisodia S., Cleveland D., et al. Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons. Proc. Natl. Acad. Sci. USA. 1995;92:954&#x2013;958. doi: 10.1073/pnas.92.4.954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.4.954</ArticleId><ArticleId IdType="pmc">PMC42615</ArticleId><ArticleId IdType="pubmed">7862672</ArticleId></ArticleIdList></Reference><Reference><Citation>Trist B.G., Hilton J.B., Hare D.J., Crouch P.J., Double K.L. Superoxide Dismutase 1 in Health and Disease: How a Frontline Antioxidant Becomes Neurotoxic. Angew. Chem. Int. Ed. Engl. 2021;60:9215&#x2013;9246. doi: 10.1002/anie.202000451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.202000451</ArticleId><ArticleId IdType="pmc">PMC8247289</ArticleId><ArticleId IdType="pubmed">32144830</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotunno M.S., Bosco D.A. An emerging role for misfolded wild-type SOD1 in sporadic ALS pathogenesis. Front. Cell Neurosci. 2013;7:253. doi: 10.3389/fncel.2013.00253.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2013.00253</ArticleId><ArticleId IdType="pmc">PMC3863749</ArticleId><ArticleId IdType="pubmed">24379756</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotunno M.S., Auclair J.R., Maniatis S., Shaffer S.A., Agar J., Bosco D.A. Identification of a misfolded region in superoxide dismutase 1 that is exposed in amyotrophic lateral sclerosis. J. Biol. Chem. 2014;289:28527&#x2013;28538. doi: 10.1074/jbc.M114.581801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.581801</ArticleId><ArticleId IdType="pmc">PMC4192504</ArticleId><ArticleId IdType="pubmed">25164820</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Johnson J.L., Agar N.Y., Agar J.N. Protein aggregation and protein instability govern familial amyotrophic lateral sclerosis patient survival. PLoS Biol. 2008;6:e170. doi: 10.1371/journal.pbio.0060170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.0060170</ArticleId><ArticleId IdType="pmc">PMC2486295</ArticleId><ArticleId IdType="pubmed">18666828</ArticleId></ArticleIdList></Reference><Reference><Citation>Medinas D.B., Rozas P., Mart&#xed;nez Traub F., Woehlbier U., Brown R.H., Bosco D.A., Hetz C. Endoplasmic reticulum stress leads to accumulation of wild-type SOD1 aggregates associated with sporadic amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 2018;115:201801109. doi: 10.1073/pnas.1801109115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1801109115</ArticleId><ArticleId IdType="pmc">PMC6094144</ArticleId><ArticleId IdType="pubmed">30038021</ArticleId></ArticleIdList></Reference><Reference><Citation>Guareschi S., Cova E., Cereda C., Ceroni M., Donetti E., Bosco D.A., Trotti D., Pasinelli P. An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1. Proc. Natl. Acad. Sci. USA. 2012;109:5074&#x2013;5079. doi: 10.1073/pnas.1115402109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1115402109</ArticleId><ArticleId IdType="pmc">PMC3324021</ArticleId><ArticleId IdType="pubmed">22416121</ArticleId></ArticleIdList></Reference><Reference><Citation>Ezzi S.A., Urushitani M., Julien J.P. Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J. Neurochem. 2007;102:170&#x2013;178. doi: 10.1111/j.1471-4159.2007.04531.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.04531.x</ArticleId><ArticleId IdType="pubmed">17394546</ArticleId></ArticleIdList></Reference><Reference><Citation>Trist B.G., Genoud S., Roudeau S., Rookyard A., Abdeen A., Cottam V., Hare D.J., White M., Altvater J., Fifita J.A., et al. Altered SOD1 maturation and post-translational modification in amyotrophic lateral sclerosis spinal cord. Brain. 2022;145:3108&#x2013;3130. doi: 10.1093/brain/awac165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac165</ArticleId><ArticleId IdType="pmc">PMC9473357</ArticleId><ArticleId IdType="pubmed">35512359</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller C., Berry J.D., McKenna-Yasek D.M., Gernoux G., Owegi M.A., Pothier L.M., Douthwright C.L., Gelevski D., Luppino S.D., Blackwood M., et al. SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS. N. Engl. J. Med. 2020;383:151&#x2013;158. doi: 10.1056/NEJMoa2005056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2005056</ArticleId><ArticleId IdType="pubmed">32640133</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T., Cudkowicz M., Shaw P.J., Andersen P.M., Atassi N., Bucelli R.C., Genge A., Glass J., Ladha S., Ludolph A.L., et al. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 2020;383:109&#x2013;119. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Boros B.D., Schoch K.M., Kreple C.J., Miller T.M. Antisense Oligonucleotides for the Study and Treatment of ALS. Neurotherapeutics. 2022;19:1145&#x2013;1158. doi: 10.1007/s13311-022-01247-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-022-01247-2</ArticleId><ArticleId IdType="pmc">PMC9587169</ArticleId><ArticleId IdType="pubmed">35653060</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M., Gulati S., Smoot E., Jaffa M., Maher N., Hyman B.T., Ivinson A.J., Scherzer C.R., Schoenfeld D.A., Cudkowicz M.E., et al. Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic lateral sclerosis. Amyotroph Lateral. Scler. 2011;12:430&#x2013;438. doi: 10.3109/17482968.2011.585163.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2011.585163</ArticleId><ArticleId IdType="pmc">PMC3446817</ArticleId><ArticleId IdType="pubmed">22023190</ArticleId></ArticleIdList></Reference><Reference><Citation>Elchuri S., Oberley T.D., Qi W., Eisenstein R.S., Jackson Roberts L., Van Remmen H., Epstein C.J., Huang T.T. CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life. Oncogene. 2005;24:367&#x2013;380. doi: 10.1038/sj.onc.1208207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1208207</ArticleId><ArticleId IdType="pubmed">15531919</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo T., Reaume A.G., Huang T.T., Carlson E., Murakami K., Chen S.F., Hoffman E.K., Scott R.W., Epstein C.J., Chan P.H. Reduction of CuZn-superoxide dismutase activity exacerbates neuronal cell injury and edema formation after transient focal cerebral ischemia. J. Neurosci. 1997;17:4180&#x2013;4189. doi: 10.1523/JNEUROSCI.17-11-04180.1997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.17-11-04180.1997</ArticleId><ArticleId IdType="pmc">PMC6573543</ArticleId><ArticleId IdType="pubmed">9151735</ArticleId></ArticleIdList></Reference><Reference><Citation>Reaume A.G., Elliott J.L., Hoffman E.K., Kowall N.W., Ferrante R.J., Siwek D.F., Wilcox H.M., Flood D.G., Beal M.F., Brown R.H., Jr., et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat. Genet. 1996;13:43&#x2013;47. doi: 10.1038/ng0596-43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0596-43</ArticleId><ArticleId IdType="pubmed">8673102</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J.M., Reaume A.G., Flood D.G., Scott R.W., Kowall N.W., Ferrante R.J., Siwek D.F., Upton-Rice M., Brown R.H., Jr. Mice lacking cytosolic copper/zinc superoxide dismutase display a distinctive motor axonopathy. Neurology. 1999;53:1239&#x2013;1246. doi: 10.1212/WNL.53.6.1239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.53.6.1239</ArticleId><ArticleId IdType="pubmed">10522879</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata N., Asayama K., Hirano A., Kobayashi M. Immunohistochemical study on superoxide dismutases in spinal cords from autopsied patients with amyotrophic lateral sclerosis. Dev. Neurosci. 1996;18:492&#x2013;498. doi: 10.1159/000111445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000111445</ArticleId><ArticleId IdType="pubmed">8940623</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson P.A., Ernhill K., Andersen P.M., Bergemalm D., Brannstrom T., Gredal O., Nilsson P., Marklund S.L. Minute quantities of misfolded mutant superoxide dismutase-1 cause amyotrophic lateral sclerosis. Brain. 2004;127:73&#x2013;88. doi: 10.1093/brain/awh005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh005</ArticleId><ArticleId IdType="pubmed">14534160</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn L.I., Houseweart M.K., Kato S., Anderson K.L., Anderson S.D., Ohama E., Reaume A.G., Scott R.W., Cleveland D.W. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science. 1998;281:1851&#x2013;1854. doi: 10.1126/science.281.5384.1851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.281.5384.1851</ArticleId><ArticleId IdType="pubmed">9743498</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Y., Wang J., Henderson M.J., Yang P., Hagen B.M., Siddique T., Vogel B.E., Deng H.X., Fang S. Nuclear export of misfolded SOD1 mediated by a normally buried NES-like sequence reduces proteotoxicity in the nucleus. eLife. 2017;6:e23759. doi: 10.7554/eLife.23759.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.23759</ArticleId><ArticleId IdType="pmc">PMC5449186</ArticleId><ArticleId IdType="pubmed">28463106</ArticleId></ArticleIdList></Reference><Reference><Citation>Saccon R.A., Bunton-Stasyshyn R.K.A., Fisher E.M.C., Fratta P. Is SOD1 loss of function involved in amyotrophic lateral sclerosis? Brain A J. Neurol. 2013;136:2342&#x2013;2358. doi: 10.1093/brain/awt097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt097</ArticleId><ArticleId IdType="pmc">PMC3722346</ArticleId><ArticleId IdType="pubmed">23687121</ArticleId></ArticleIdList></Reference><Reference><Citation>Trist B.G., Davies K.M., Cottam V., Genoud S., Ortega R., Roudeau S., Carmona A., De Silva K., Wasinger V., Lewis S.J.G., et al. Amyotrophic lateral sclerosis-like superoxide dismutase 1 proteinopathy is associated with neuronal loss in Parkinson&#x2019;s disease brain. Acta Neuropathol. 2017;134:113&#x2013;127. doi: 10.1007/s00401-017-1726-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1726-6</ArticleId><ArticleId IdType="pubmed">28527045</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi S., Fujiwara N., Ido A., Oono M., Takeuchi Y., Tateno M., Suzuki K., Takahashi R., Tooyama I., Taniguchi N., et al. Induction of protective immunity by vaccination with wild-type apo superoxide dismutase 1 in mutant SOD1 transgenic mice. J. Neuropathol. Exp. Neurol. 2010;69:1044&#x2013;1056. doi: 10.1097/NEN.0b013e3181f4a90a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3181f4a90a</ArticleId><ArticleId IdType="pubmed">20838241</ArticleId></ArticleIdList></Reference><Reference><Citation>Urushitani M., Ezzi S.A., Julien J.-P. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 2007;104:2495&#x2013;2500. doi: 10.1073/pnas.0606201104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0606201104</ArticleId><ArticleId IdType="pmc">PMC1790867</ArticleId><ArticleId IdType="pubmed">17277077</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H.N., Tjostheim S., Dasilva K., Taylor D., Zhao B., Rakhit R., Brown M., Chakrabartty A., McLaurin J., Robertson J. Targeting of monomer/misfolded SOD1 as a therapeutic strategy for amyotrophic lateral sclerosis. J. Neurosci. 2012;32:8791&#x2013;8799. doi: 10.1523/JNEUROSCI.5053-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5053-11.2012</ArticleId><ArticleId IdType="pmc">PMC6622344</ArticleId><ArticleId IdType="pubmed">22745481</ArticleId></ArticleIdList></Reference><Reference><Citation>Gros-Louis F., Soucy G., Lariviere R., Julien J.P. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J. Neurochem. 2010;113:1188&#x2013;1199. doi: 10.1111/j.1471-4159.2010.06683.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2010.06683.x</ArticleId><ArticleId IdType="pubmed">20345765</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier M., Welt T., Wirth F., Montrasio F., Preisig D., McAfoose J., Vieira F.G., Kulic L., Sp&#xe4;ni C., Stehle T., et al. A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis. Sci. Transl. Med. 2018;10:eaah3924. doi: 10.1126/scitranslmed.aah3924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aah3924</ArticleId><ArticleId IdType="pubmed">30518612</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva-Pilipich N., Smerdou C., Vanrell L. A Small Virus to Deliver Small Antibodies: New Targeted Therapies Based on AAV Delivery of Nanobodies. Microorganisms. 2021;9:1956. doi: 10.3390/microorganisms9091956.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9091956</ArticleId><ArticleId IdType="pmc">PMC8465657</ArticleId><ArticleId IdType="pubmed">34576851</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghadge G.D., Kay B.K., Drigotas C., Roos R.P. Single chain variable fragment antibodies directed against SOD1 ameliorate disease in mutant SOD1 transgenic mice. Neurobiol. Dis. 2019;121:131&#x2013;137. doi: 10.1016/j.nbd.2018.08.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.08.021</ArticleId><ArticleId IdType="pubmed">30176351</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel P., Kriz J., Gravel M., Soucy G., Bareil C., Gravel C., Julien J.P. Adeno-associated virus-mediated delivery of a recombinant single-chain antibody against misfolded superoxide dismutase for treatment of amyotrophic lateral sclerosis. Mol. Ther. 2014;22:498&#x2013;510. doi: 10.1038/mt.2013.239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2013.239</ArticleId><ArticleId IdType="pmc">PMC3944333</ArticleId><ArticleId IdType="pubmed">24394188</ArticleId></ArticleIdList></Reference><Reference><Citation>Muyldermans S. A guide to: Generation and design of nanobodies. FEBS J. 2021;288:2084&#x2013;2102. doi: 10.1111/febs.15515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.15515</ArticleId><ArticleId IdType="pmc">PMC8048825</ArticleId><ArticleId IdType="pubmed">32780549</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee D., Bhatt M., Butler D., De Genst E., Dobson C.M., Messer A., Kordower J.H. Proteasome-targeted nanobodies alleviate pathology and functional decline in an alpha-synuclein-based Parkinson&#x2019;s disease model. NPJ Park. Dis. 2018;4:25. doi: 10.1038/s41531-018-0062-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-018-0062-4</ArticleId><ArticleId IdType="pmc">PMC6105584</ArticleId><ArticleId IdType="pubmed">30155513</ArticleId></ArticleIdList></Reference><Reference><Citation>Pothin E., Lesuisse D., Lafaye P. Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR. Pharmaceutics. 2020;12:937. doi: 10.3390/pharmaceutics12100937.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics12100937</ArticleId><ArticleId IdType="pmc">PMC7601373</ArticleId><ArticleId IdType="pubmed">33007904</ArticleId></ArticleIdList></Reference><Reference><Citation>Danis C., Dupre E., Zejneli O., Caillierez R., Arrial A., Begard S., Mortelecque J., Eddarkaoui S., Loyens A., Cantrelle F.X., et al. Inhibition of Tau seeding by targeting Tau nucleation core within neurons with a single domain antibody fragment. Mol. Ther. 2022;30:1484&#x2013;1499. doi: 10.1016/j.ymthe.2022.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2022.01.009</ArticleId><ArticleId IdType="pmc">PMC9077319</ArticleId><ArticleId IdType="pubmed">35007758</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco D.A., Morfini G., Karabacak N.M., Song Y., Gros-Louis F., Pasinelli P., Goolsby H., Fontaine B.A., Lemay N., McKenna-Yasek D., et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat. Neurosci. 2010;13:1396&#x2013;1403. doi: 10.1038/nn.2660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2660</ArticleId><ArticleId IdType="pmc">PMC2967729</ArticleId><ArticleId IdType="pubmed">20953194</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H.X., Hentati A., Tainer J.A., Iqbal Z., Cayabyab A., Hung W.Y., Getzoff E.D., Hu P., Herzfeldt B., Roos R.P., et al. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. Science. 1993;261:1047&#x2013;1051. doi: 10.1126/science.8351519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8351519</ArticleId><ArticleId IdType="pubmed">8351519</ArticleId></ArticleIdList></Reference><Reference><Citation>Molnar K.S., Karabacak N.M., Johnson J.L., Wang Q., Tiwari A., Hayward L.J., Coales S.J., Hamuro Y., Agar J.N. A common property of amyotrophic lateral sclerosis-associated variants: Destabilization of the copper/zinc superoxide dismutase electrostatic loop. J. Biol. Chem. 2009;284:30965&#x2013;30973. doi: 10.1074/jbc.M109.023945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.023945</ArticleId><ArticleId IdType="pmc">PMC2781497</ArticleId><ArticleId IdType="pubmed">19635794</ArticleId></ArticleIdList></Reference><Reference><Citation>Rechsteiner M., Rogers S.W. PEST sequences and regulation by proteolysis. Trends Biochem. Sci. 1996;21:267&#x2013;271. doi: 10.1016/S0968-0004(96)10031-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0968-0004(96)10031-1</ArticleId><ArticleId IdType="pubmed">8755249</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler D.C., Joshi S.N., Genst E., Baghel A.S., Dobson C.M., Messer A. Bifunctional Anti-Non-Amyloid Component alpha-Synuclein Nanobodies Are Protective In Situ. PLoS ONE. 2016;11:e0165964. doi: 10.1371/journal.pone.0165964.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0165964</ArticleId><ArticleId IdType="pmc">PMC5100967</ArticleId><ArticleId IdType="pubmed">27824888</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi S.N., Butler D.C., Messer A. Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies. MAbs. 2012;4:686&#x2013;693. doi: 10.4161/mabs.21696.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/mabs.21696</ArticleId><ArticleId IdType="pmc">PMC3502235</ArticleId><ArticleId IdType="pubmed">22929188</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler D.C., Messer A. Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments. PLoS ONE. 2011;6:e29199. doi: 10.1371/journal.pone.0029199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0029199</ArticleId><ArticleId IdType="pmc">PMC3245261</ArticleId><ArticleId IdType="pubmed">22216210</ArticleId></ArticleIdList></Reference><Reference><Citation>Crapo J.D., Oury T., Rabouille C., Slot J.W., Chang L.Y. Copper, zinc superoxide dismutase is primarily a cytosolic protein in human cells. Proc. Natl. Acad. Sci. USA. 1992;89:10405&#x2013;10409. doi: 10.1073/pnas.89.21.10405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.89.21.10405</ArticleId><ArticleId IdType="pmc">PMC50347</ArticleId><ArticleId IdType="pubmed">1332049</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez J.A., Valentine J.S., Eggers D.K., Roe J.A., Tiwari A., Brown R.H., Hayward L.J. Familial amyotrophic lateral sclerosis-associated mutations decrease the thermal stability of distinctly metallated species of human copper/zinc superoxide dismutase. J. Biol. Chem. 2002;277:15932&#x2013;15937. doi: 10.1074/jbc.M112088200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112088200</ArticleId><ArticleId IdType="pubmed">11854285</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt D.R., Lee M.K., Slunt H.S., Guarnieri M., Xu Z.S., Wong P.C., Brown R.H., Jr., Price D.L., Sisodia S.S., Cleveland D.W. Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proc. Natl. Acad. Sci. USA. 1994;91:8292&#x2013;8296. doi: 10.1073/pnas.91.17.8292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.91.17.8292</ArticleId><ArticleId IdType="pmc">PMC44592</ArticleId><ArticleId IdType="pubmed">8058797</ArticleId></ArticleIdList></Reference><Reference><Citation>Boopathy S., Silvas T.V., Tischbein M., Jansen S., Shandilya S.M., Zitzewitz J.A., Landers J.E., Goode B.L., Schiffer C.A., Bosco D.A. Structural basis for mutation-induced destabilization of profilin 1 in ALS. Proc. Natl. Acad. Sci. USA. 2015;112:7984&#x2013;7989. doi: 10.1073/pnas.1424108112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1424108112</ArticleId><ArticleId IdType="pmc">PMC4491777</ArticleId><ArticleId IdType="pubmed">26056300</ArticleId></ArticleIdList></Reference><Reference><Citation>Auclair J.R., Boggio K.J., Petsko G.A., Ringe D., Agar J.N. Strategies for stabilizing superoxide dismutase (SOD1), the protein destabilized in the most common form of familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 2010;107:21394&#x2013;21399. doi: 10.1073/pnas.1015463107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1015463107</ArticleId><ArticleId IdType="pmc">PMC3003092</ArticleId><ArticleId IdType="pubmed">21098299</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao K., Oerlemans R., Groves M.R. Theory and applications of differential scanning fluorimetry in early-stage drug discovery. Biophys. Rev. 2020;12:85&#x2013;104. doi: 10.1007/s12551-020-00619-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12551-020-00619-2</ArticleId><ArticleId IdType="pmc">PMC7040159</ArticleId><ArticleId IdType="pubmed">32006251</ArticleId></ArticleIdList></Reference><Reference><Citation>Niesen F.H., Berglund H., Vedadi M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2007;2:2212&#x2013;2221. doi: 10.1038/nprot.2007.321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2007.321</ArticleId><ArticleId IdType="pubmed">17853878</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H., Qian K., Du Z., Cao J., Petersen A., Liu H., Blackbourn L.W.t., Huang C.L., Errigo A., Yin Y., et al. Modeling ALS with iPSCs reveals that mutant SOD1 misregulates neurofilament balance in motor neurons. Cell Stem Cell. 2014;14:796&#x2013;809. doi: 10.1016/j.stem.2014.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2014.02.004</ArticleId><ArticleId IdType="pmc">PMC4230530</ArticleId><ArticleId IdType="pubmed">24704493</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiskinis E., Sandoe J., Williams L.A., Boulting G.L., Moccia R., Wainger B.J., Han S., Peng T., Thams S., Mikkilineni S., et al. Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. Cell Stem Cell. 2014;14:781&#x2013;795. doi: 10.1016/j.stem.2014.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2014.03.004</ArticleId><ArticleId IdType="pmc">PMC4653065</ArticleId><ArticleId IdType="pubmed">24704492</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigamonti A., Repetti G.G., Sun C., Price F.D., Reny D.C., Rapino F., Weisinger K., Benkler C., Peterson Q.P., Davidow L.S., et al. Large-Scale Production of Mature Neurons from Human Pluripotent Stem Cells in a Three-Dimensional Suspension Culture System. Stem Cell Rep. 2016;6:993&#x2013;1008. doi: 10.1016/j.stemcr.2016.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2016.05.010</ArticleId><ArticleId IdType="pmc">PMC4912437</ArticleId><ArticleId IdType="pubmed">27304920</ArticleId></ArticleIdList></Reference><Reference><Citation>Robberecht W.I.M., Rousseau F., Schymkowitz J. Sinlge Domain Antibodies against SOD1 and Their Use in Medicine. 2014/191493 A1. WO. 2014 May 28;</Citation></Reference><Reference><Citation>Shvil N., Banerjee V., Zoltsman G., Shani T., Kahn J., Abu-Hamad S., Papo N., Engel S., Bernhagen J., Israelson A. MIF inhibits the formation and toxicity of misfolded SOD1 amyloid aggregates: Implications for familial ALS. Cell Death Dis. 2018;9:107. doi: 10.1038/s41419-017-0130-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-017-0130-4</ArticleId><ArticleId IdType="pmc">PMC5833700</ArticleId><ArticleId IdType="pubmed">29371591</ArticleId></ArticleIdList></Reference><Reference><Citation>Sau D., De Biasi S., Vitellaro-Zuccarello L., Riso P., Guarnieri S., Porrini M., Simeoni S., Crippa V., Onesto E., Palazzolo I., et al. Mutation of SOD1 in ALS: A gain of a loss of function. Hum. Mol. Genet. 2007;16:1604&#x2013;1618. doi: 10.1093/hmg/ddm110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddm110</ArticleId><ArticleId IdType="pubmed">17504823</ArticleId></ArticleIdList></Reference><Reference><Citation>Trist B.G., Hare D.J., Double K.L. A Proposed Mechanism for Neurodegeneration in Movement Disorders Characterized by Metal Dyshomeostasis and Oxidative Stress. Cell Chem. Biol. 2018;25:807&#x2013;816. doi: 10.1016/j.chembiol.2018.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2018.05.004</ArticleId><ArticleId IdType="pubmed">29861271</ArticleId></ArticleIdList></Reference><Reference><Citation>Hossain M.A., Sarin R., Donnelly D.P., Miller B.C., Salisbury J.P., Conway J.B., Watson S., Winters J.N., Alam N., Sivasankar D., et al. Protein crosslinking as a therapeutic strategy for SOD1-related ALS. bioRxiv. 2021 doi: 10.1101/2021.06.23.449516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.23.449516</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts B.R., Lim N.K., McAllum E.J., Donnelly P.S., Hare D.J., Doble P.A., Turner B.J., Price K.A., Lim S.C., Paterson B.M., et al. Oral treatment with Cu(II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci. 2014;34:8021&#x2013;8031. doi: 10.1523/JNEUROSCI.4196-13.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4196-13.2014</ArticleId><ArticleId IdType="pmc">PMC6608261</ArticleId><ArticleId IdType="pubmed">24899723</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilton J.B., Mercer S.W., Lim N.K., Faux N.G., Buncic G., Beckman J.S., Roberts B.R., Donnelly P.S., White A.R., Crouch P.J. Cu(II)(atsm) improves the neurological phenotype and survival of SOD1(G93A) mice and selectively increases enzymatically active SOD1 in the spinal cord. Sci. Rep. 2017;7:42292. doi: 10.1038/srep42292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep42292</ArticleId><ArticleId IdType="pmc">PMC5304223</ArticleId><ArticleId IdType="pubmed">28205575</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikseresht S., Hilton J.B.W., Kysenius K., Liddell J.R., Crouch P.J. Copper-ATSM as a Treatment for ALS: Support from Mutant SOD1 Models and Beyond. Life. 2020;10:271. doi: 10.3390/life10110271.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life10110271</ArticleId><ArticleId IdType="pmc">PMC7694234</ArticleId><ArticleId IdType="pubmed">33158182</ArticleId></ArticleIdList></Reference><Reference><Citation>Abel O., Powell J.F., Andersen P.M., Al-Chalabi A. ALSoD: A user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum. Mutat. 2012;33:1345&#x2013;1351. doi: 10.1002/humu.22157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22157</ArticleId><ArticleId IdType="pubmed">22753137</ArticleId></ArticleIdList></Reference><Reference><Citation>Pleiner T., Bates M., Trakhanov S., Lee C.T., Schliep J.E., Chug H., B&#xf6;hning M., Stark H., Urlaub H., G&#xf6;rlich D. Nanobodies: Site-specific labeling for super-resolution imaging, rapid epitope-mapping and native protein complex isolation. eLife. 2015;4:e11349. doi: 10.7554/eLife.11349.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.11349</ArticleId><ArticleId IdType="pmc">PMC4755751</ArticleId><ArticleId IdType="pubmed">26633879</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey S., Gorlich D. A new set of highly efficient, tag-cleaving proteases for purifying recombinant proteins. J. Chromatogr. A. 2014;1337:95&#x2013;105. doi: 10.1016/j.chroma.2014.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chroma.2014.02.029</ArticleId><ArticleId IdType="pubmed">24636565</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron D.M., Kaushansky L.J., Ward C.L., Sama R.R.K., Chian R.-J., Boggio K.J., Quaresma A.J.C., Nickerson J.A., Bosco D.A. Amyotrophic lateral sclerosis-linked FUS/TLS alters stress granule assembly and dynamics. Mol. Neurodegener. 2013;8:30. doi: 10.1186/1750-1326-8-30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-8-30</ArticleId><ArticleId IdType="pmc">PMC3766239</ArticleId><ArticleId IdType="pubmed">24090136</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y.C., Kumar M.S., Ramesh N., Anderson E.N., Nguyen A.T., Kim B., Cheung S., McDonough J.A., Skarnes W.C., Lopez-Gonzalez R., et al. Interactions between ALS-linked FUS and nucleoporins are associated with defects in the nucleocytoplasmic transport pathway. Nat. Neurosci. 2021;24:1077&#x2013;1088. doi: 10.1038/s41593-021-00859-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00859-9</ArticleId><ArticleId IdType="pmc">PMC8832378</ArticleId><ArticleId IdType="pubmed">34059832</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>